Neonatal diethylstilbestrol exposure disrupts uterine epithelial apical-basal polarity and partial EMT state

Rachel E Bainbridge1, Wendy N Jefferson1, Tianyuan Wang2

  • 1Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Durham, NC 27709.

Insights

Neonatal exposure to diethylstilbestrol (DES) disrupts uterine development in mice by altering cell differentiation, stem cell populations, and tissue structure. This reprogramming of developmental trajectories increases long-term risks for infertility and gynecologic cancers.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Developmental toxicology

Background:

  • The developing female reproductive tract is sensitive to hormonal disruption.
  • Estrogenic chemicals like diethylstilbestrol (DES) can cause infertility and gynecologic diseases.

Purpose of the Study:

  • To investigate the cell type-specific effects of neonatal DES exposure on the developing mouse uterus.
  • To elucidate the molecular mechanisms underlying DES-induced uterine abnormalities.

Main Methods:

  • Mouse model of neonatal exposure to diethylstilbestrol (DES).
  • Analysis of uterine epithelial and mesenchymal cell differentiation, stem cell populations (Lgr5+), and extracellular matrix (ECM) deposition.
  • Investigation of chromatin accessibility, gene expression, chromatin looping, and estrogen receptor alpha (ERα) binding.

Main Results:

  • DES exposure altered uterine epithelial-mesenchymal transition, caused premature differentiation, and depleted Lgr5+ stem cells.
  • DES disrupted cell-cell communication, aberrantly activated Wnt signaling, and induced fibrosis in the mesenchyme.
  • DES exposure induced cell type-specific changes in chromatin accessibility and gene expression, linked to altered chromatin looping and ERα binding.

Conclusions:

  • Developmental exposure to DES reprograms cell differentiation and ECM characteristics in the uterus.
  • These changes contribute to long-term functional impairment and increased cancer risk.
  • Findings suggest similar risks from other estrogenic endocrine-disrupting chemicals.